Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7863287 | GLAXOSMITHKLINE | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(2 years from now) |
Advil Allergy Sinus is owned by Glaxosmithkline.
Advil Allergy Sinus contains Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride.
Advil Allergy Sinus has a total of 1 drug patent out of which 0 drug patents have expired.
Advil Allergy Sinus was authorised for market use on 19 December, 2002.
Advil Allergy Sinus is available in tablet;oral dosage forms.
The generics of Advil Allergy Sinus are possible to be released after 28 February, 2027.
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL